Researchers have discovered that a subtle chemical change to protein p21 acts as a master regulator of cell division – a finding that could influence future cancer therapies. 

The study was launched at the Biotechnology Center (BIOTEC) of TUD Dresden University of Technology in Germany and later conducted by researchers at The Institute of Cancer Research, London, UK. 

The researchers found that this switch determines whether cells continue to grow or enter senescence, where they stop dividing permanently. 

The research team used a technique known as redox proteomics, which maps how reactive oxygen species (ROS) chemically modify proteins. Although associated with cell damage, these molecules also act as important messengers, helping regulate cellular processes like stress response and cell division.  

The researchers labelled and analysed more than 1,700 individual oxidation sites across various proteins, carefully tracking their changes throughout the cell cycle. In doing so, they created one of the most detailed maps of redox activity during cell division to date. 

They focused on p21 after noticing that its oxidation peaked just before the cells divided. The study found that the oxidation of a single site on p21 – a cysteine amino acid at position 41 (C41) – is key to determining how the protein behaves and interacts with other proteins. 

When this site is oxidised, which occurs just before a cell divides, p21 is broken down, allowing cells to keep reproducing. But when the site is not oxidised – due to mutation or lack of reactive oxygen – p21 becomes more stable and cells are more likely to enter senescence. 

This oxidation acts as a chemical switch – part of a broader redox mechanism where oxygen-based chemical changes help control protein function – that helps steer cells towards growth or permanent arrest. 

A new layer of regulation in the cell cycle 

While these findings are still early-stage, they reveal a powerful mechanism that could be relevant in a range of diseases – especially cancer. Manipulating the redox state of p21 could offer a new entry point for therapies, particularly treatment-resistant cells that are difficult to eliminate with conventional approaches. 

The researchers suggest this redox control may be important in improving responses to treatments like radiotherapy or drugs that lead to an increase in p21 levels.   

Dr Julia Vorhauser, co-lead author and Postdoctoral Training Fellow in the Post-translational Modifications and Cell Proliferation Group, said: “By understanding how p21’s oxidation state controls its stability and interactions, we’ve uncovered a completely new layer of regulation in the cell cycle. This could be a useful target in cancer – especially in tumours where p21 is present but misregulated.” 

The team is now looking at how this redox switch behaves in different types of cancer and trying to determine whether it could be exploited to design better combination treatments.

Diana Turner, Senior Digital Content Editor, DDW